Keisuke Kitakaze Selected Research

lysoganglioside G(M2)

1/2011

Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Keisuke Kitakaze Research Topics

Disease

3	GM2 Gangliosidoses (GM2 Gangliosidosis) 09/2016 - 06/2011
2	Lysosomal Storage Diseases (Lysosomal Storage Disease) 09/2016 - 01/2016
2	Tay-Sachs Disease 06/2011 - 01/2011
2	Sandhoff Disease (Sandhoff's Disease) 06/2011 - 01/2011
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022
1	Body Weight (Weight, Body) 12/2021
1	Neoplasms (Cancer) 01/2021
1	Fibrosis (Cirrhosis) 01/2020

Drug/Important Bio-Agent (IBA)

3	Hexosaminidase BIBA 09/2016 - 06/2011
3	Hexosaminidase A (Hex A)IBA 01/2016 - 01/2011
2	Hexosaminidases (Hexosaminidase)IBA 09/2016 - 06/2011
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022
1	sephin1IBA 12/2021
1	lysophosphatidic acidIBA 01/2021
1	LipidsIBA 01/2021
1	Growth Differentiation Factor 15IBA 01/2020
1	Bleomycin (Blenoxane)FDA LinkGeneric 01/2020
1	G(M2) Activator ProteinIBA 09/2016
1	Fluorescent Dyes (Fluorescent Probes)IBA 01/2016
1	Mannose (D-Mannose)IBA 01/2016
1	Peptide Hydrolases (Proteases)FDA Link 01/2016
1	lysoganglioside G(M2)IBA 01/2011
1	GangliosidesIBA 01/2011
1	Biomarkers (Surrogate Marker)IBA 01/2011

Therapy/Procedure

2	Therapeutics 09/2016 - 01/2016
2	Enzyme Replacement Therapy 01/2016 - 06/2011